Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05974839 · ClinicalTrials.gov registry record
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
A clinical trial, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- 732
- Enrollment target
NCT05974839: Completed study, sponsored by State University of New York at Buffalo.
NCT05974839 is a clinical trial that has completed, run by State University of New York at Buffalo. The registered enrollment target is 732 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05974839 has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- 732 participants
- Enrollment target
Study Summary
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
Primary Outcome
Cortical lesion accumulation as measured using MRI between subjects on placebo and subjects who took ocrelizumab.
Interventions
- OTHER Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 732 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2024-02-28 |
What the finished NCT05974839 record still lists
NCT05974839 is an observational study that tracks outcomes without assigning an intervention. The registered 732 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT05974839 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05974839 about?
NCT05974839 is a clinical study titled "Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)". The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
What is the current status of trial NCT05974839?
This trial is currently completed. The enrollment target is 732 participants. The study started on 2023-10-01. Estimated completion is 2024-02-28.
What interventions are being tested in trial NCT05974839?
The interventions under investigation include: Ocrelizumab (OTHER).
Who is sponsoring clinical trial NCT05974839?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216301 · 734 participants · Phase 3
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- NCT07231419 · 734 participants · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI